GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Resverlogix Corp (TSX:RVX) » Definitions » Shiller PE Ratio

Resverlogix (TSX:RVX) Shiller PE Ratio : (As of Jun. 02, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Resverlogix Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Resverlogix Shiller PE Ratio Historical Data

The historical data trend for Resverlogix's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Resverlogix Shiller PE Ratio Chart

Resverlogix Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Resverlogix Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Resverlogix's Shiller PE Ratio

For the Biotechnology subindustry, Resverlogix's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Resverlogix's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Resverlogix's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Resverlogix's Shiller PE Ratio falls into.



Resverlogix Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Resverlogix's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Resverlogix's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.004/126.2576*126.2576
=0.004

Current CPI (Mar. 2024) = 126.2576.

Resverlogix Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201404 -1.517 98.920 -1.936
201407 0.086 99.315 0.109
201410 -0.045 99.473 -0.057
201501 -0.024 98.209 -0.031
201504 -0.296 99.710 -0.375
201507 0.039 100.579 0.049
201510 -0.052 100.500 -0.065
201601 -0.114 100.184 -0.144
201604 -0.128 101.370 -0.159
201607 -0.078 101.844 -0.097
201610 -0.186 102.002 -0.230
201701 -0.158 102.318 -0.195
201704 -0.148 103.029 -0.181
201707 -0.178 103.029 -0.218
201710 -0.126 103.424 -0.154
201801 -0.186 104.056 -0.226
201804 -0.025 105.320 -0.030
201807 -0.368 106.110 -0.438
201810 -0.273 105.952 -0.325
201901 -0.093 105.557 -0.111
201904 -0.428 107.453 -0.503
201907 0.026 108.243 0.030
201910 0.607 107.927 0.710
202001 0.026 108.085 0.030
202004 0.056 107.216 0.066
202007 -0.040 108.401 -0.047
202010 -0.026 108.638 -0.030
202103 0.000 110.298 0.000
202106 -0.012 111.720 -0.014
202109 -0.025 112.905 -0.028
202112 -0.090 113.774 -0.100
202203 -0.013 117.646 -0.014
202206 -0.002 120.806 -0.002
202209 -0.013 120.648 -0.014
202212 0.014 120.964 0.015
202303 -0.027 122.702 -0.028
202306 -0.013 124.203 -0.013
202309 -0.027 125.230 -0.027
202312 -0.013 125.072 -0.013
202403 0.004 126.258 0.004

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Resverlogix  (TSX:RVX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Resverlogix Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Resverlogix's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Resverlogix (TSX:RVX) Business Description

Traded in Other Exchanges
Address
4820 Richard Road South West, Suite 300, Calgary, AB, CAN, T3E 6L1
Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.
Executives
Aaron Bradley Cann Senior Officer

Resverlogix (TSX:RVX) Headlines

No Headlines